Promising results with prostate cancer
"These are the most powerful results from prostate cancer trials," said Nicholas James, the foremost author of the American Society of Clinical Oncology. "This is a single sense of career, which is one of the greatest deaths I have seen in adult cancer clinical trials.
Researchers used standard hormone therapy and a drug called Aviraterone. Aviraterone is normally only used for cancer patients who no longer respond to hormone therapy. This study was conducted as part of the Stampede Test, an ongoing randomized trial conducted in the UK and Switzerland.
"Abilateron not only prolongs life but also reduces the likelihood of recurrence by 70% and reduces the probability of serious bone complications by 50%," James said. "Based on the magnitude of the clinical benefit, the prospective care of newly diagnosed patients with advanced prostate cancer should change," he said.
In this study, 2,000 men gathered. Patients who received both aviraterone and normal hormone therapy had significantly lower mortality than those who received hormonal therapy alone.
Relatively, 83% of men who received avilateron therapy survived 76% of men with standard hormone therapy. Researchers also discovered that patients taking both medications were particularly somewhat stronger in cardiovascular and liver side effects.
One patient, Alfred Samuels (59 years old) who participated in this study, was diagnosed with prostate cancer progressed in January 2012. "I felt my world weakened all night," the doctor explained, "Since surgery spread across the prostate gland, surgery is not my option.
"As part of the trial, I began taking Avilaterone four times a day and received hormonal injections every eight weeks. When I conducted an examination in the first 6 months I was shown that the treatment was effective I am still in trial.I am relieved.Fortunately, my cancer is well managed.
According to the Center for Disease Control and Prevention (CDC), more than 27,000 prostate cancer patients in the UK died each year in the U.S. More than 11,000 people die in the UK each year. In the United States, besides skin cancer, it is the most common cancer in men.
"The potential benefits of combining avilaterone and hormonal therapy are obviously impressive and will cooperate with relevant agencies so that these men will be able to select this treatment through NHS," prostate cancer UK .
EmoticonEmoticon